This article is more than 5 years old. Information may no longer be current.

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Issue: May 2019 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1 open-label trial examining the feasibility and safety of combining CIML NK cells with the donor lymphocyte infusion approach to significantly enhance the graft versus leukemia and provide potentially curative therapy for patients with an otherwise extremely poor prognosis.